Area of research
Oncology · Public Health, Environmental and Occupational Health
Research interest
Research interests include CAR-T cell therapy research, Acute Lymphoblastic Leukemia research, Glioma Diagnosis and Treatment, and Immunotherapy and Immune Responses.
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
Abstract 959: Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients
Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia
Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS
Mediport use as an acceptable standard for CAR T cell infusion
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework